Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection. Nucala injection ...

If you take Zepbound, a doctor or another healthcare professional will likely give you the first dose in their office. Then, they’ll show you or someone else how to inject Zepbound at home. You can ...

Injection site reactions are the most common side effect of Emgality. The most frequent injection site reaction is pain. But there are steps you can take to help prevent or reduce pain from Emgality ...

Bimzelx is prescribed for moderate to severe plaque psoriasis, psoriatic arthritis, non-radiographic axial spondyloarthritis, ankylosing spondylitis, and moderate to severe hidradenitis suppurativa in ...

Kesimpta is a medicine used to treat relapsing forms of multiple sclerosis (MS). Relapsing forms of MS include clinically isolated syndrome, relapsing-remitting MS, and active secondary progressive MS ...

This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. It’s hard to watch the news or scroll through social media without encountering stories about weight loss drugs like semaglutide (the ...

On December 22, 2025, the U.S. Food and Drug Administration (FDA) approved an oral pill form of Wegovy — a glucagon-like peptide-1 (GLP-1) receptor agonist medication for weight loss. Until now, ...

Subcutaneous nivolumab and hyaluronidase-nvhy is FDA-approved for adult solid tumors, offering a new administration route for PD-1 inhibitors. The phase 3 CheckMate-67T trial confirmed noninferiority ...

Kristie Reed, PharmD, oversees emergency, general medical, surgical, psychiatric care, and oncology medication as the pharmacy director of a community hospital. Dr. Reed specializes in IV medications.

Subcutaneous injections are a routine yet critical nursing skill that demands precision, safety, and confidence. Recent studies show both face-to-face and video-based training improve nurse competence ...

The US Food and Drug Administration (FDA) has approved the biologics license application for a subcutaneous formulation of lecanemab (Leqembi Iqlik) for weekly maintenance dosing to treat Alzheimer’s ...

Basel, 16 September 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the United States Food and Drug Administration (U.S. FDA) has approved OCREVUS ZUNOVO™ (ocrelizumab & hyaluronidase-ocsq) ...